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ABSTRACT  
Drug induced galactorrhea is a condition of increased prolactin level in the serum resulting in irregular menstrual cycle and galactorrhea in 
women. Levosulpiride is a novel drug with antipsychotic, anti-depressant, anti-emetic and anti-dyspeptic actions. Galactorrhea is the secretion 
of milky discharge from breast in men or women who are not breastfeeding for one year. It may result from excessive secretion of prolactin or 
increased sensitivity of breast tissue to prolactin.  A rare case on levosulpiride induced elevated serum prolactin level presenting as a 
distressing adverse effect of galactorrhoea in a female patient was reported. It’s important to keep a watch on prolactin levels during treatment 
with levosulpiride. For patients who present as a confirmed case of hyperprolactinemia, it is important to exclude other causes of prolactin 
elevation. Reporting the case would be a learning point for the fellow pharmacists and health care professionals in optimizing the therapy and 
requirement of strict monitoring of prescription that would minimize the medication errors. 
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INTRODUCTION 
Levosulpiride is the levorotatory enantiomer of sulpiride, a 
substituted benzamide. It is gastro protective agent which is 
used for different dyspeptic symptoms underlying with 
varied etiologies. Apart, it is meant to use in other conditions 
including depression, psychosis, somatoform disorders, 
premature ejaculation and burning mouth syndrome. It is a 
novel drug with antipsychotic, antidepressant, antiemetic 
and anti-dyspeptic actions. The main action of levosulpiride 
is D2 dopaminergic receptor blockade; those located on the 
presynaptic membrane of the dopaminergic pathways in the 
central nervous system and gastrointestinal tract. The 
antagonistic action on central D2 receptors leading to the 
therapeutic action as well as due to its inhibiting nature 
towards prolactin resulting adverse effect i.e. 
hyperprolactinemia1. 
Galactorrhea is the secretion of milky discharge from breast 
in men or women who are not breastfeeding for one year. It 
may result from excessive secretion of prolactin or increased 
sensitivity of breast tissue to prolactin. Most of the times it is 
caused by elevation of prolactin and is often associated with 
menstrual abnormalities. Prolactin is a peptide hormone 
released from anterior pituitary which in turn is regulated 
predominantly by inhibitory effect of dopamine and to a 
small extent by the stimulatory effect of thyrotropin-
releasing hormone, oxytocin, vasopressin, vasoactive 
intestinal peptide and angiotensin-II2. Any condition that 
produces imbalance in these substances can lead to 
elevation of prolactin and cause galactorrhea and menstrual 
abnormalities3. Varied conditions like stimulation of breast, 
chest wall diseases, drugs or pathological conditions like 
pituitary tumors can cause galactorrhea as a symptom. 
Drugs like antipsychotics, antidepressants, estrogen-
containing drugs, prokinetics, antihypertensives, opioids 
that act by blocking D2 receptors or decrease synthesis of 
dopamine can reduce the hypothalamic inhibitory tone on 
pituitary and thereby can increase in prolactin secretion 
which may cause galactorrhea4. 
Usually the prolactin elevation due to drugs is <100ng/ml 
except for few antipsychotics which can increase up to 250 
ng/ml4,5. According to Petit et al. the rates of 
hyperprolactinemia according to therapeutic drug classes 
were 31% associated with neuroleptics, 28% with 
neuroleptic-like drugs, 26% with antidepressants, 5% with 
H2-receptor antagonists, and 10% with other drugs5. Recent 
increased use of D2 blockers for the treatment of gastro 
esophageal reflux disease (GERD) seems to have increased 
the prevalence of hyperprolactinemia and galactorrhea due 
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to D2 blockers as we have observed in our clinical practice6. 
Presenting the case with the concern of the patient. 
Objective:  
To report a case of levosulpiride Induced Galactorrhea. 
CASE REPORT:  
A non-pregnant female patient of age 38 years contacted a 
secondary care hospital with chief complaint of galactorrhea. 
All her vital signs were normal and her past medical history 
was summarized in the Table 1. 
 
Table 1: Scheduling of consultant visits 
No. of 
visits 
Complaints Consultant 
Physician 
Investigations Diagnosis Medications 
1 Neurologist LBA since 4 
years, Increased 
pain since 15 
days, radiating 
to lower limb, 
burning 
sensation in 
abdomen 
MRI-LUMBO-SACRAL 
SPINE: 
-Protruded L3-L4 
Disc  causing compression 
on thecal sac and neural 
foramina, indenting on 
transvering and exiciting 
nerve roots - Degenerated 
L4- L5 Disc 
Lumbar PIVD 1) Diclofenac sodium 
100mg OD (sos) 
2) Tolperisone 450mg OD 
3)Pregabalin 75mg+ 
Nortriptylie 10mg OD 
4)Pantaprazole 40mg OD 
2 Neurologist With increased 
LBA, paresthesia 
of left lower 
limb especially 
in night, Head 
ache since 2 
days, Vomiting 1 
episode the day 
before the visit. 
No investigations     advised. Lumbar PIVD 1)Diclofenac gel 
2)Diclofenac sodium 
100mg OD(sos) 
3) Tab gabapentin 100mg 
morning 300mg evening  
4) Pantaprazole 40mg+ 
levosulpirid 75mg OD 
5) Lumbar support belt 
 
3 Gynaecologist Galactorrhea Serum prolactin : 40 ng/ml Hyperprolact
inemia 
Referred to ndocrinologist 
 
4 Endocrinologist Galactorrhea No investigation Drug Induced 
Hyperprolact
inemia 
Cabergolin 0.25 mg 2 
times a week. 
 
 
Since local and central causes of hyperprolcatinemi were 
ruled out a diagnosis of levosulpiride-induced galactorrhoea 
was arrived based on the existing data. Causality assessment 
was carried out using the Naranjo's causality assessment 
scale which showed highly probable causal association. 
DISCUSSION 
Serum prolactin levels ranged from 40ng/ml to 261.81 
ng/ml for drug-associated galactorrhea and 140 ng /ml to 
3241 ng/ml for prolactinoma. There was a considerable 
overlap between the serum prolactin levels of drug-induced 
galactorrhea and that of prolactinoma. A study by Fujino et 
al.7 on the effect of intravenous domperidone on healthy 
volunteers had shown serum prolactin rise above 160 ng/ml 
in 15 minutes in some cases. Even low-dose amisulpiride can 
elevate serum prolactin levels to 110.7 ± 49.3 ng/ml in 
females. So, drug intake can commonly lead to increase in 
serum prolactin more than 100 ng/ml and often more than 
200ng/ml 8. Few case reports have also reported that 
levosulpiride and domperidone-induced galactorrhea can be 
associated with serum prolactin of more than 100 ng/ml and 
sometimes up to 271ng/ml. Hence, history of drug intake 
should always be elicited in all patients with galactorrhea or 
hyperprolactinemia before considering further evaluation 
9,10. This would avoid the unnecessary costly investigations. 
However, a serum prolactin of >300 ng/ml is unlikely to be 
associated with prokinetic use and can be considered for 
further evaluation of hyperprolactinemia. 
Stopping the implicated drug for 72 hours or more and 
repeating serum prolactin level helps to confirm the drug-
induced galactorrhea. However, it should be kept in mind 
that serum prolactin may not normalize by 72 hours in few 
patients and may take a week or more to do so. But all 
patients with drug-induced galactorrhea had at least 50% 
fall in serum prolactin by 72 hours of stopping the 
implicated drug and the same can be used as a criterion to 
define drug-induced hyperprolactinemia. These patients can 
be followed up till 2 weeks after stopping the drug for 
further normalization of serum prolactin. 
Apart from being an anti-psychotic and prokinetic agent, 
levosulpiride also shows its efficacy in treating 
chemotherapy induced nausea and vomiting1. The role of 5-
HT4 receptor stimulation has also been postulated as a 
prokinetic agent. It is known to cause movement disorders, 
dopaminergic inhibitions in the nigrostriatal pathways 
resulting in parkinson’s characters acute dystonia, rabbit 
syndrome, akathesia.  Levosulpiride can block the 
dopaminergic receptors which are normally inhibitory in 
nature with respect to prolactin release thus leading to 
increased prolactin secretion resulting in hyper-
prolactinemia. Hyperprolactinemia is a side effect occurring 
with all antidopaminergic prokinetics however in this case it 
is not recommended to indicate levosulpiride for one 
episode of vomiting for duration of 30 days which has lead 
to the development of galactorrhea. 
Intervention 
Levosulpiride is not recommended in this case for one 
episode of non chemotherapy induced vomiting and it has 
been given for a period of 30 days which is not advisable. 
CONCLUSION 
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Finally, Pharmacist and health care professionals should 
consider checking the history of antipsychotic drugs (even 
though the indication may differ) in patients presenting with 
galactorrhea. It’s important to keep a watch on prolactin 
levels during treatment with levosulpiride. For patients who 
present as a confirmed case of hyperprolactinemia, it is 
important to exclude other causes of prolactin elevation 
such as tumors in the hypothalamic-pituitary area, 
pregnancy, hypothyroidism and chronic renal insufficiency. 
Prokinetic use was the most common cause of galactorrhea 
in our study and treated with D2 agonists. Hence, there is a 
need to ensure measures to reduce the non-specific use of 
prokinetics and increase awareness regarding the 
occurrence of galactorrhea with prokinetics use, to reduce 
unnecessary investigations and treatment. Galactorrhea is 
an adverse drug reaction not commonly encountered. Hence, 
physicians should be aware of such uncommon side effects 
of common drugs to avert unnecessary worry and 
intervention. 
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